| Authors: |
Pugsley MK; Cytokinetics, Toxicology & Safety Pharmacology, South San Francisco, CA, USA., Bhatt S; Pfizer, Safety Sciences, Drug Safety Research and Development, Groton, CT, USA., Gottfridsson C; AstraZeneca, Cardiovascular Safety Center of Excellence, CMO, Patient Safety, Oncology R&D, Gothenburg, Sweden., Hoffmann P; Independent, Beaufort, SC, USA., Koshman YE; AbbVie, Safety Pharmacology, North Chicago, IL, USA., Norton K; Charles River Laboratories, Safety Pharmacology, Senneville, Quebec, Canada., O'Brien CE; Health and Environmental Sciences Institute, Washington, DC, USA., Pierson J; Health and Environmental Sciences Institute, Washington, DC, USA. Electronic address: jpierson@hesiglobal.org., Rossman EI; GSK, Safety Pharmacology, Collegeville, PA, 19426, USA., Taraboletti A; Health and Environmental Sciences Institute, Washington, DC, USA., Zabka TS; Genentech, Development Sciences-Safety Assessment, San Francisco, CA, USA., Foley CM; AbbVie, Safety Pharmacology, North Chicago, IL, USA. |
